Neurotechnology startup Mave Health has secured $2.1 million in funding, led by Blume Ventures, to further develop its wearable headset designed to enhance focus, mood, and stress regulation.
The wearable headset utilizes transcranial direct current stimulation (tDCS) to target the prefrontal cortex through brief daily sessions. Weighing around 100g, the device delivers low-intensity electrical stimulation to brain regions associated with attention and emotional regulation, providing benefits during daily activities and lasting up to a month on a single charge.
Users can track their progress and personalize protocols via Mave’s companion app, without collecting sensitive brain data. The company reports that users have experienced significant improvements within a few weeks of use, with positive effects accumulating over time. The product is currently available for pre-order in the US and India, with shipments set to commence in April 2026.
Mave Health’s approach has garnered interest, with early sales and endorsements from tech leaders and athletes, such as UFC fighter Max Griffin. The company’s focus on non-invasive neurotechnology aims to enhance mental well-being and productivity.
Source: Entrackr : Latest Posts